Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALLIUM: Obinutuzumab vs Rituximab in Untreated Indolent NHL
NCT01332968Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2011
- Primary completion
- Feb 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of obinutuzumab in Non-Hodgkin lymphoma (NHL), sponsored by Roche. Started Jul 2011; status: completed.
02
Drugs
obinutuzumab
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01332968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332968.